Open AccessELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution
Author(s) -
I V Poddubnaya,
Поддубная Ирина Владимировна,
Lyubov Al-Radi,
Аль-Ради Любовь Саттаровна,
Tatyana Byalik,
Бялик Татьяна Евгеньевна,
Kamil Kaplanov,
Капланов Камиль Даниялович,
Valentina Molostvova,
Молоствова Валентина Захаровна,
Е.С. Никитин,
Никитин Евгений Александрович,
Т И Поспелова,
Поспелова Татьяна Ивановна,
В. В. Птушкин,
Птушкин Вадим Вадимович,
Olga Samoilova,
Самойлова Ольга Сергеевна,
Elena Stadnik,
Стадник Елена Александровна,
Gayane Tumyan,
Тумян Гаяне Сергеевна
Publication year - 2020
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/18151434.2020.1.200090
Subject(s) - chronic lymphocytic leukemia , bruton's tyrosine kinase , medicine , regimen , first line treatment , obinutuzumab , oncology , first line , leukemia , tyrosine kinase , chemotherapy , receptor
Over the past decade, we have seen a significant change in modern approaches in the first-line treatment of chronic lymphocytic leukemia (CLL). The CLL-10 study data established the FCR regimen as the treatment of choice for younger patients with limited comorbidities, while for patients older than 65 years, the BR regimen is more often considered as less toxic one. According to published data, 46% of patients with newly diagnosed CLL have comorbidities. Moreover, high-risk patients with del(17p) and/or TP53 mutation do not have response on immunochemotherapy (ICT) most often. Thus, about 1/2 of the patients cannot be treated or will not respond to standard ICT regimens. Targeted therapy with Brutons tyrosine kinase (BTK) inhibitors is an important option of the first-line treatment of patients with CLL. Acalabrutinib is a highly selective second-generation BTK inhibitor that does not inhibit EGFR, ITK or TEC targets. Acalabrutinib in combination with obinutuzumab or as monotherapy can be considered as a highly effective and safe option of the first line of CLL therapy. Based on the hight selectivity of the agent, acalabrutinib can be considered as the preferable option for patients who are not eligible for ICT, including patients with commodities, such as cardiovascular diseases or risk factors for their development.